Search & Analyze

Aurobindo Pharma Ltd.

HealthcarePharmaceuticals & Drugs

www.aurobindo.com BSE: 524804NSE: AUROPHARMA

₹1,569.30BSE3.49%

23 Oct, 4:01 PM

₹1,569.30

₹90.29K Cr

24.32

2.32

9.93%

₹1,608.95

₹1,548.15

₹1,739.95

₹1,080.10

Customise metrics bar

Aurobindo Pharma Ltd. (AUROPHARMA) share price closed at ₹1,569.30 on the BSE on Friday, October 23, 2026, down by 3.49% from its of ₹1,626.00. In that session AUROPHARMA reached a of 1,608.95 and of 1,548.15. The for the session was 1,566.80. The stands at 1,661.40 and is at 1,446.46. Looking at , the stock ended the session moving sideways.

Stock Overview

Symbol

AUROPHARMA

₹1,608.95

₹1,626.00

₹1,566.80

₹1,661.40

Price 5.54% below

₹1,446.46

Price 8.49% above

34.79% of range

₹1,548.15₹1,608.95

74.14% of range

₹1,080.10₹1,739.95

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,743.00	34.58	4,18,204.09	0.92	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	8,984.00	81.54	2,38,496.97	0.33	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,482.00	80.26	1,70,480.87	0.85	534.00	-9.64%	4,979.00	50.79%	19.27
ZYDUSLIFE ZYDUSLIFE	1,127.85	24.93	1,12,503.47	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,337.00	32.04	1,08,012.30	0.97	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,974.00	97.55	1,06,657.63	0.10	362.07	123.94%	2,026.31	29.10%	18.20
DR.REDDY'S DRREDDY	1,224.50	36.50	1,02,206.60	0.65	913.20	-31.69%	8,697.80	-1.48%	13.75
Aurobindo Pharma Ltd. AUROPHARMA	1,569.30	24.32	90,294.05	0.25	1,032.03	25.22%	9,150.35	16.30%	12.76

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	7,580.15	7,567.02	7,796.07	7,978.52	8,382.12	7,868.14	8,285.70	8,645.90	8,853.34	9,150.35
Expenses	5,907.34	5,947.45	6,229.93	6,400.54	6,590.20	6,265.11	6,607.60	6,872.56	7,100.56	7,269.29
	1,672.81	1,619.57	1,566.14	1,577.98	1,791.92	1,603.03	1,678.10	1,773.34	1,752.78	1,881.06
	22.07%	21.40%	20.09%	19.78%	21.38%	20.37%	20.25%	20.51%	19.80%	20.56%
	13.51	220.93	136.00	157.29	134.81	105.30	120.59	122.31	117.04	224.05
Interest	89.43	111.04	112.70	118.48	115.02	97.75	95.24	92.77	98.21	101.66
	354.33	404.18	382.28	418.53	444.43	405.70	429.19	464.73	478.57	486.82
	1,229.90	1,323.89	1,207.46	1,199.85	1,335.09	1,206.80	1,275.92	1,338.52	1,290.61	1,515.09
	26.23%	30.64%	32.34%	29.53%	32.38%	31.70%	33.53%	32.03%	28.65%	31.88%
	908.75	919.22	817.38	845.81	903.47	824.75	848.45	910.29	921.26	1,032.56
	15.51	15.69	14.07	14.56	15.56	14.20	14.61	15.67	15.86	17.95

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	47,811.72	50,860.13	59,784.10	63,558.91	69,519.14
	23,455.49	24,855.38	29,001.87	31,723.73	33,653.08
EXPENDITURE :
Increase/Decrease in Stock	816.68	-409.68	-946.17	-597.63	-294.81
Raw Material Consumed	8,422.23	10,600.16	12,294.95	12,269.52	12,309.21
Power & Fuel Cost	626.86	842.63	826.03	1,012.25	1,117.61
Employee Cost	3,450.92	3,522.25	3,922.94	4,475.62	5,190.17
Other Manufacturing Expenses	2,502.98	2,810.03	3,191.71	3,556.25	3,760.09
General and Administration Expenses	1,335.03	1,386.66	1,483.77	1,551.60	1,763.42
Selling and Distribution Expenses	1,496.67	1,685.76	1,684.72	2,185.06	2,254.93
Miscellaneous Expenses	419.58	698.93	700.92	688.27	735.13
	19,070.95	21,136.74	23,158.87	25,140.94	26,835.75
Operating Profit (Excl OI)	4,384.54	3,718.64	5,843.00	6,582.79	6,817.33
	322.58	290.59	557.38	621.85	520.49
	4,707.12	4,009.23	6,400.38	7,204.64	7,337.82
Interest	48.64	140.48	289.71	457.24	383.97
PBDT	4,658.48	3,868.75	6,110.67	6,747.40	6,953.85
	1,126.52	1,244.58	1,521.66	1,649.42	1,778.19
Profit Before Taxation & Exceptional Items	3,531.96	2,624.17	4,589.01	5,097.98	5,175.66
Exceptional Income / Expenses	-127.97		-191.86		-65.33
	3,372.74	2,612.50	4,379.99	5,066.29	5,111.85
Provision for Tax	725.63	684.85	1,211.02	1,582.72	1,608.88
	2,647.11	1,927.65	3,168.97	3,483.57	3,502.97
Extra items				0.00	0.00
Minority Interest	1.04	-0.15	4.00	2.31	1.78
Consolidated Net Profit	2,648.15	1,927.50	3,172.97	3,485.88	3,504.75
Profit Balance B/F	20,136.76	22,518.99	23,910.41	26,801.42	30,221.65
Appropriations	22,784.91	24,446.49	27,083.38	30,287.30	33,726.40
Equity Dividend %	900.00%	300.00%	450.00%		400.00%
	45.20	32.90	54.16	60.02	60.34
Adjusted EPS	45.20	32.90	54.16	60.02	60.34

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	58.59	58.59	58.59	58.08	58.08
Total Reserves	24,517.39	26,781.26	29,784.21	32,595.24	37,832.89
Reserve excluding Revaluation Reserve	24,517.39	26,781.26	29,784.21	32,595.24	37,832.89
Revaluation reserve	0.00
	24,575.98	26,839.85	29,842.80	32,653.32	37,890.97
Minority Interest	-1.93	12.00	8.00	-6.39	-8.16
Secured Loans	249.21	618.96	2,134.90	1,159.38	798.20
Unsecured Loans				402.27	4.55
Deferred Tax Assets / Liabilities	122.37	-287.88	-856.08	-989.69	-1,177.59
Other Long Term Liabilities	359.73	363.07	304.42	307.85	1,071.17
Long Term Provisions	171.79	172.72	225.70	282.93	400.41
Total Non-Current Liabilities	903.10	866.87	1,808.94	1,162.74	1,096.74
Trade Payables	2,703.05	3,871.31	4,454.16	4,188.85	5,567.27
Other Current Liabilities	3,106.51	2,979.91	3,161.05	4,462.78	5,828.46
Short Term Borrowings	2,117.83	4,230.43	4,078.12	5,470.22	6,079.64
Short Term Provisions	228.59	412.13	505.80	560.49	563.64
Total Current Liabilities	8,155.98	11,493.78	12,199.13	14,682.34	18,039.01
Total Liabilities	33,633.13	39,212.50	43,858.87	48,492.01	57,018.56
Gross Block	15,943.09	18,593.32	23,447.77	24,462.96	29,251.05
Less: Accumulated Depreciation	5,411.00	7,569.63	8,952.24	9,668.77	11,844.47
Less: Impairment of Assets			2.74
Net Block	10,532.09	11,023.69	14,492.79	14,794.19	17,406.58
Capital Work in Progress	2,937.56	4,496.40	2,739.39	3,266.00	3,008.83
Non Current Investments	618.30	391.74	321.65	251.70	303.88
Long Term Investment	618.30	391.74	321.65	251.70	303.88
Long Term Loans & Advances	575.33	794.00	714.55	973.42	971.58
Other Non Current Assets	37.52	67.39	255.53	410.28	414.21
Total Non-Current Assets	15,510.44	17,666.83	19,653.24	21,329.55	24,309.81
Currents Investments	378.85	151.00	50.58	0.01	747.24
Inventories	7,553.85	8,511.23	9,808.23	10,543.72	12,052.94
Sundry Debtors	4,012.26	4,466.38	4,816.74	5,745.93	7,094.37
Cash and Bank	4,190.01	6,084.20	6,278.30	8,235.49	9,870.29
Other Current Assets	393.95	554.71	519.45	654.00	398.75
Short Term Loans and Advances	1,514.67	1,692.39	2,298.62	1,983.31	2,545.16
Total Current Assets	18,043.59	21,459.91	23,771.92	27,162.46	32,708.75
Net Current Assets (Including Current Investments)	9,887.61	9,966.13	11,572.79	12,480.12	14,669.74
Total Assets	33,633.13	39,212.50	43,858.87	48,492.01	57,018.56
Contingent Liabilities	157.74	158.53	311.34	1,290.26	1,358.37
Total Debt	2,372.77	4,861.52	6,315.22	7,941.68	7,676.20
	419.46	458.10	509.35	562.21	652.39
Adjusted Book Value	419.46	458.10	509.35	562.21	652.39

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	3,372.74	2,612.50	4,379.99	5,066.29	5,111.85
Adjustment	1,344.13	1,586.47	1,496.24	1,834.16	2,082.62
Changes In working Capital	1,557.80	-1,094.98	-1,675.07	-1,244.48	163.93
Cash Flow after changes in Working Capital	6,274.67	3,103.99	4,201.16	5,655.97	7,358.40
Cash Flow from Operating Activities	5,016.48	2,386.75	2,434.52	3,924.62	5,526.37
Cash Flow from Investing Activities	-3,211.56	-3,977.75	-4,255.95	-1,875.80	-3,458.61
Cash Flow from Financing Activitie	-2,969.27	1,814.41	800.42	119.78	-1,269.15
Net Cash Inflow / Outflow	-1,164.35	223.41	-1,021.01	2,168.60	798.61
Opening Cash & Cash Equivalents	5,329.91	4,162.51	4,392.27	3,385.43	5,563.79
Cash & Cash Equivalent of Subsidiaries under liquidations	-3.25	6.41		0.66	0.18
Effect of Foreign Exchange Fluctuations	0.20	-0.06	14.17	9.10	828.82
Closing Cash & Cash Equivalent	4,162.51	4,392.27	3,385.43	5,563.79	7,191.40

Ratios

Valuation

24.32

2.32

11.33

2.60

64.52

676.49

Profitability

9.93

12.76

6.64

9.81

5.04

Leverage & Liquidity

0.20

1.81

14.31

Returns

0.25

1.32

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26	Sep '26
	51.80	51.82	51.82	51.82	51.82	51.82	51.82	51.82	51.88	51.88
	41.50	41.72	41.49	41.56	41.30	41.81	41.63	41.11	41.48	41.83
	6.70	6.46	6.69	6.61	6.87	6.38	6.56	7.08	6.64	6.29
	48.20	48.18	48.18	48.18	48.18	48.18	48.18	48.18	48.12	48.12
No. of Shareholders	2,38,622	2,48,488	2,57,962	2,69,323	2,72,208	2,47,662	2,36,859	2,41,298	2,39,073	2,33,737

Mutual Funds Invested(266)

Based on each fund's latest monthly portfolio · Sep 2026

A total of 164 active funds hold 15.76% in Aurobindo Pharma Ltd., contributing to ₹15.16K Cr of holdings

Fund				As of
HD HDFC Mid Cap Fund - Growth - Direct PlanMid Cap Fund	2,231.24	2.19	1,33,44,745	Sep '26
QU Quant ELSS Tax Saver Fund - Growth - Direct PlanEquity - ELSS - Tax Saver Fund	1,112.26	8.49	66,52,259	Sep '26
QU Quant Mid Cap Fund - Growth - Direct PlanMid Cap Fund	819.76	10.71	49,02,846	Sep '26
SB SBI Large & Midcap Fund - Growth - Direct PlanLarge & Mid Cap	785.84	1.94	47,00,000	Sep '26
QU Quant Multi Cap Fund - Growth - Direct PlanMulti Cap Fund	711.82	9.49	42,57,303	Sep '26
SB SBI Flexicap Fund - Growth - Direct PlanFlexi Cap Fund	670.12	3.03	40,07,877	Sep '26
SB SBI Midcap Fund - Growth - Direct PlanMid Cap Fund	508.04	2.18	30,38,512	Sep '26
QU Quant Flexi Cap Fund - Growth - Direct PlanFlexi Cap Fund	502.33	6.87	30,04,373	Sep '26
HD HDFC Balanced Advantage Fund - Growth - Direct PlanHybrid - Balanced Advantage	451.51	0.44	27,00,437	Sep '26
HD HDFC Large & Mid Cap Fund - Growth - Direct PlanLarge & Mid Cap	361.16	1.27	21,60,032	Sep '26

Corporate Actions

Showing: All

Date	Type	Details
2026-07-29	AGM
2026-07-27	Board Meeting	Quarterly Results
2026-05-12	Board Meeting	Audited Results

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Aurobindo Pharma Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

11 members across the board and senior leadership

Mangalam Ramasubramanian Kumar

Chairman

₹37.00 L

Mar '26

K Nityananda Reddy

Vice Chairman & Managing Director

₹5.47 Cr

Mar '26

M Madan Mohan Reddy

Whole Time Director

₹6.98 Cr

Mar '26

Santanu Mukherjee

Non Executive Independent Director

₹41.00 L

Mar '26

Girish Paman Vanvari

Non Executive Independent Director

₹42.00 L

Mar '26

Punita Kumar Sinha

Non Executive Independent Director

₹6.80 L

Mar '26

Deepali Pant Joshi

Non Executive Independent Director

₹36.00 L

Mar '25

P Sarath Chandra Reddy

Non Independent & Non Executive Director

₹8.00 L

Mar '26

PV Ramprasad Reddy

Promoter & Non-Executive Director

₹5.00 L

Mar '26

Satakarni Makkapati

Non Independent & Non Executive Director

₹9.00 L

Mar '26

B Adi Reddy

Company Secretary & Compliance Officer

—

AUROPHARMA Latest News

News

10 of 10 articles

EQUITY9 Oct 2026 · 14:44

Aurobindo Pharma informs about newspaper publication

EQUITY5 Oct 2026 · 10:21

Aurobindo Pharma rises on getting USFDA’s final nod to manufacture, market Perampanel tablets

The product will be manufactured at Unit-IV of APL Healthcare, a wholly-owned subsidiary of the company and will be launched in Q3FY27

COMPANY5 Oct 2026 · 09:58

Aurobindo Pharma gets USFDA’s final nod to manufacture, market Perampanel tablets

The product will be manufactured at Unit-IV of APL Healthcare, a wholly-owned subsidiary of the company and will be launched in Q3FY27

EQUITY24 Sept 2026 · 12:31

Aurobindo Pharma informs about closure of trading window

COMPANY16 Sept 2026 · 12:58

USFDA concludes inspection at Aurobindo Pharma’s arm’s Telangana facility

The inspection concluded with one observation, which is procedural in nature

EQUITY15 Sept 2026 · 16:16

Aurobindo Pharma informs about press release

COMPANY15 Sept 2026 · 16:14

Aurobindo Pharma gets USFDA’s nod for Beclomethasone Dipropionate HFA Inhalation Aerosol

The product will be manufactured at Aurobindo Pharma’s Raleigh facility in North Carolina

COMPANY11 Sept 2026 · 17:51

USFDA completes inspection at Aurobindo Pharma’s arm’s Andhra Pradesh facility

The inspection was conducted from September 7 to September 11, 2026 and concluded with zero observations

EQUITY2 Sept 2026 · 14:35

Aurobindo Pharma moves up as its arm incorporates wholly owned subsidiary

The object of incorporation of this wholly owned subsidiary is to undertake manufacturing and marketing operations in India and foreign countries

EQUITY1 Sept 2026 · 14:12

Aurobindo Pharma informs about disclosure

AUROPHARMA

₹1,569.30

-3.49%